Tag: Non-steroidal aromatase inhibitor (third generation)

Anastrozole (ZD1033, Arimidex) is a third-generation nonsteroidal aromatase inhibitor of the triazole class that selectively and reversibly inhibits the cytochrome P450 19A1 (CYP19A1, aromatase) enzyme complex responsible for the terminal step in estrogen biosynthesis: the conversion of androstenedione to estrone and testosterone to estradiol. At the approved oral dose of 1 mg once daily, anastrozole achieves greater than 96 percent suppression of plasma estradiol in postmenopausal women and approximately 97 percent inhibition of whole-body aromatase activity, without measurable effects on adrenocortical steroidogenesis, aldosterone production, or thyroid function. The compound was developed at Zeneca Pharmaceuticals (now AstraZeneca) through systematic optimization of triazole-bearing aromatase inhibitor scaffolds and received United States Food and Drug Administration approval in 1995 for the treatment of advanced breast cancer in postmenopausal women following tamoxifen therapy, with subsequent label expansions to first-line advanced disease (2000) and adjuvant treatment of early-stage hormone receptor-positive breast cancer (2002).

The pivotal Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial, enrolling 9,366 postmenopausal women with early-stage invasive breast cancer, established anastrozole as superior to tamoxifen on disease-free survival, time to recurrence, time to distant recurrence, and incidence of contralateral breast cancer at 100-month and 10-year analyses, with a carryover benefit extending beyond the 5-year treatment period. The International Breast Cancer Intervention Study II (IBIS-II) subsequently demonstrated a 49 percent reduction in breast cancer incidence in high-risk postmenopausal women receiving anastrozole 1 mg daily for 5 years compared to placebo, with a persistent preventive effect beyond the active treatment period at 131 months of median follow-up. Anastrozole is now among the most widely prescribed endocrine therapies in oncology, with established roles in adjuvant, neoadjuvant, extended adjuvant, and chemoprevention settings for estrogen receptor-positive breast cancer.

Pharmacokinetics are characterized by rapid oral absorption (time to peak concentration approximately 2 hours), high oral bioavailability (approximately 85 percent), extensive hepatic metabolism through N-dealkylation, hydroxylation, and glucuronidation (with a principal inactive triazole metabolite), and a long terminal elimination half-life of 40 to 50 hours that supports once-daily dosing and achieves steady-state plasma concentrations within approximately 7 days. Anastrozole is not a potent inhibitor or inducer of cytochrome P450 enzymes at therapeutic concentrations, and clinically significant drug-drug interactions are uncommon. The compound is well tolerated; the principal adverse events are hot flashes, arthralgia, fatigue, and musculoskeletal stiffness, with the most clinically significant long-term safety signal being accelerated bone mineral density loss and increased fracture risk attributable to profound estrogen suppression, managed in clinical practice through concurrent bisphosphonate therapy and bone density monitoring.

Beyond the oncology indication, anastrozole has been investigated as an off-label research tool for modulating the hypothalamic-pituitary-gonadal axis in males, where aromatase inhibition reduces the conversion of testosterone to estradiol, relieves estrogen-mediated negative feedback on gonadotropin secretion, and increases endogenous testosterone production. This application remains investigational and is not approved by regulatory authorities. This monograph reviews the chemistry, synthesis, and structural class of anastrozole; the molecular pharmacology of aromatase inhibition; the comprehensive pharmacokinetic record; preclinical pharmacology; the clinical evidence base across adjuvant, neoadjuvant, chemoprevention, and investigational indications; sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signals; and a comparative assessment of five alternative aromatase-modulating agents against anastrozole on five competency standards.

Letrozole (4,4′-(1H-1,2,4-triazol-1-ylmethylene)bis(benzonitrile); CAS 112809-51-5; molecular formula C17H11N5; molecular weight 285.31) is a non-steroidal third-generation aromatase inhibitor developed at Novartis and approved by the FDA in 1997 under the trade name Femara. The compound is a more potent aromatase inhibitor than anastrozole, reducing plasma estradiol by approximately 88 to 99 percent at a 2.5 mg daily dose in postmenopausal women. The greater potency translates to slightly superior progression-free survival in head-to-head trials versus anastrozole in metastatic breast cancer, with similar tolerability. Plasma half-life is approximately 42 hours; metabolism is hepatic via CYP2A6 and CYP3A4. Approved indications include adjuvant and metastatic ER-positive postmenopausal breast cancer; off-label use in PCOS-related anovulatory infertility (often more effective than clomiphene per the PPCOS II trial) and as estrogen control in androgen-using populations. Used as the most potent reference aromatase inhibitor.